Sign in

    Imogen Mansfield

    Research Analyst at Cantor Fitzgerald

    Imogen Mansfield is Vice President of Biotech Equity Research at Cantor Fitzgerald in New York, specializing in the analysis of biotechnology companies and industry trends. She actively covers publicly listed biopharmaceutical firms such as Agios Pharmaceuticals and Incyte Corporation, frequently participating in earnings calls and industry conferences on behalf of Cantor's healthcare research team; however, specific public rankings or quantitative performance metrics are not available at this time. Having begun her career after graduating from Stanford University, Mansfield has developed a strong reputation within the sector and maintains over 500 professional connections in the financial research community. Her professional credentials include a robust background in equity research, but publicly available sources do not confirm current securities licenses or FINRA registration.

    Imogen Mansfield's questions to AGIOS PHARMACEUTICALS (AGIO) leadership

    Imogen Mansfield's questions to AGIOS PHARMACEUTICALS (AGIO) leadership • Q2 2025

    Question

    Imogen Mansfield of Cantor Fitzgerald inquired about any updates to the safety profile of ometipivat (Pyrokine), specifically regarding liver toxicity, and asked for more details on the expected approval timeline in the GCC region.

    Answer

    Chief Medical Officer Dr. Sarah Gheuens confirmed there were no new updates to the drug's safety profile. CEO Brian Goff stated that regulatory filings were submitted simultaneously in four regions and discussions are active, but did not provide a specific timeline for the GCC approval.

    Ask Fintool Equity Research AI